ONCSQ (OncoSec Medical) LT-Debt-to-Total-Asset: 0.24 (As of Jan. 2023)


What is OncoSec Medical LT-Debt-to-Total-Asset?

OncoSec Medical ONCSQ -99.00% LT-Debt-to-Total-Asset is 0.24 as of Jan. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OncoSec Medical's long-term debt to total assests ratio for the quarter that ended in Jan. 2023 was 0.24.

OncoSec Medical's long-term debt to total assets ratio increased from Jan. 2022 (0.13) to Jan. 2023 (0.24). It may suggest that OncoSec Medical is progressively becoming more dependent on debt to grow their business.

OncoSec Medical  (OTCPK:ONCSQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OncoSec Medical LT-Debt-to-Total-Asset Related Terms

OncoSec Medical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical LT-Debt-to-Total-Asset Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.21 0.09 0.19

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.16 0.19 0.24 0.24

OncoSec Medical LT-Debt-to-Total-Asset Calculation

OncoSec Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2022 is calculated as

LT Debt to Total Assets (A: Jul. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Jul. 2022 )/Total Assets (A: Jul. 2022 )
=4.127/21.878
=

OncoSec Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2023 is calculated as

LT Debt to Total Assets (Q: Jan. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2023 )/Total Assets (Q: Jan. 2023 )
=2.127/8.871
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.24 mean?
OncoSec Medical (ONCSQ) has a LT-Debt-to-Total-Asset of 0.24 as of Jan. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OncoSec Medical and its competitors.
Is OncoSec Medical's LT-Debt-to-Total-Asset too high?
OncoSec Medical's current LT-Debt-to-Total-Asset is 0.24.
How does OncoSec Medical's LT-Debt-to-Total-Asset compare to NOVNQ and USRM?
OncoSec Medical's LT-Debt-to-Total-Asset of 0.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OncoSec Medical and its competitors. OncoSec Medical's current LT-Debt-to-Total-Asset is 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current LT-Debt-to-Total-Asset of 0.24. The current LT-Debt-to-Total-Asset is 0.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current LT-Debt-to-Total-Asset is 0.24 as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.